72% reduction in hospitalisation from monoclonal antibodies, page-4

I hear you but we are not comparing apples with apples on the patient cohort here.

MSB are treating 100% of the sickest in their trials and looking for 70% success rate ideally.

This other treatment they are not treating just the 6% being hospitalized, they are treating the 100% who test positive for COVID with a 4.7% reduction in hospitalization on that whole 100% who they are treating. So then it comes down to - is it worth the cost to treat the 100% infected for a 4.7% improvement over doing nothing. That is the harsh reality of this one.

I say yes save everyone but governments won't in their cost benefit analysis.